Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.51 |
| ▸ | AR | P10275 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.46 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20511213 | 1.00 | GPR119 (0.51) | GPR119ARHRH3EGLN2NR1H2 | |
| SCHEMBL20510393 | 0.85 | GPR119 (0.50) | GPR119 | |
| SCHEMBL20511076 | 0.84 | GPR119 (0.67) | GPR119NR1H2ALDH1A1LMNAMAPT | |
| SCHEMBL27399965 | 0.84 | GPR119 (0.67) | GPR119NR1H2ALDH1A1LMNAMAPT | |
| SCHEMBL17135075 | 0.83 | HDAC1 (0.55) | GPR119NR1H2ALDH1A1LMNAMAPT | |
| SCHEMBL31288417 | 0.83 | HDAC1 (0.55) | GPR119NR1H2ALDH1A1LMNAMAPT | |
| SCHEMBL31288397 | 0.83 | HDAC1 (0.55) | GPR119NR1H2ALDH1A1LMNAMAPT | |
| SCHEMBL22523841 | 0.83 | GPR119 (0.52) | GPR119NR1H2ALDH1A1LMNAMAPT | |
| SCHEMBL22015318 | 0.83 | GPR119 (0.52) | GPR119NR1H2ALDH1A1LMNAMAPT | |
| SCHEMBL927555 | 0.83 | GPR119 (0.52) | GPR119NR1H2ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230022770-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20210024495-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | US | disclosed |
| US-20210024492-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024492-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | GPR119 1166/4885AR 4589/4885HRH3 815/4885 |
| US-20210024495-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | GPR119 1166/4885AR 4589/4885HRH3 815/4885 |
| US-20230022770-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | GPR119 1166/4885AR 4589/4885HRH3 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.